Is Aspirin a Good Treatment for Irregular Heartbeat?

Aspirin is not a good treatment for irregular heartbeat, and major cardiology guidelines no longer recommend it for stroke prevention in atrial fibrillation, the most common sustained irregular heart rhythm. For decades, aspirin was widely prescribed to people with atrial fibrillation because it was cheap, familiar, and seemed like a reasonable compromise for patients who couldn’t tolerate stronger blood thinners. The evidence, though, has accumulated in one direction: aspirin is far less effective than anticoagulants at preventing the strokes that make atrial fibrillation dangerous, and its bleeding risks are not as much lower as people assume.

Why Atrial Fibrillation Creates a Different Kind of Clot

To understand why aspirin falls short, you need to know a little about how clots form in atrial fibrillation versus, say, in a coronary artery. Aspirin works by blocking the production of a chemical called thromboxane A2, which is involved in making platelets clump together.¹ That platelet-clumping process is a big deal in heart attacks and in the kind of arterial blockages that cause many strokes. Aspirin is genuinely helpful in those situations.

Atrial fibrillation produces clots through a different route. When the upper chambers of the heart quiver instead of contracting properly, blood pools and stagnates, especially in a small pouch called the left atrial appendage. The shape and ridged inner surface of that pouch make it particularly prone to trapping slow-moving blood, which then forms clots through the coagulation cascade rather than primarily through platelet aggregation.² These are fibrin-rich clots, and aspirin’s anti-platelet action doesn’t do much to prevent them. Anticoagulants like warfarin or the newer direct oral anticoagulants target the coagulation cascade itself, which is why they work so much better in this setting.

How Aspirin Compares to Real Anticoagulants

The clinical trials on this go back decades and tell a consistent story. The Stroke Prevention in Atrial Fibrillation II study randomized over a thousand patients with atrial fibrillation to either warfarin or aspirin. In patients 75 and younger, the rate of stroke or systemic embolism was about 1.3% per year with warfarin versus 1.9% per year with aspirin. In patients over 75, those rates were 3.6% and 4.8% respectively.³ The differences didn’t quite reach statistical significance in that trial, partly because the study wasn’t large enough, but the pattern was clear: warfarin was better, and the gap widened with age.

A more definitive answer came from the BAFTA trial, which focused specifically on older adults with atrial fibrillation in community settings. That study found that warfarin cut the yearly risk of stroke, intracranial hemorrhage, or systemic embolism roughly in half compared with aspirin, from about 3.8% per year down to 1.8% per year.⁴ A review in Postgraduate Medical Journal put it bluntly: well-managed warfarin therapy is roughly twice as effective as aspirin at preventing stroke in atrial fibrillation.⁵

The newer anticoagulants have only widened the gap. The ARTESiA trial compared the direct oral anticoagulant apixaban against aspirin in patients with subclinical atrial fibrillation, meaning episodes detected by implanted devices rather than on a standard electrocardiogram. Even in this lower-risk population, apixaban reduced the rate of stroke or systemic embolism from about 1.24% per year with aspirin to 0.78% per year.⁶ The 2023 joint guideline from the American College of Cardiology, American Heart Association, and Heart Rhythm Society reflects this accumulated evidence, with updated recommendations on anticoagulation that have moved decisively away from aspirin as a stroke-prevention option in atrial fibrillation.⁷

The Bleeding Myth

One reason aspirin persisted in practice for so long is the assumption that it is meaningfully safer than anticoagulants. Many patients and even some clinicians think of aspirin as a mild, low-risk drug and anticoagulants as dangerous blood thinners. The actual data paints a more complicated picture.

In the BAFTA trial of elderly patients, the rate of serious bleeding outside the skull was essentially the same whether patients took warfarin or aspirin: about 1.4% per year with warfarin versus 1.6% per year with aspirin.⁴ When the AVERROES trial compared apixaban to aspirin in atrial fibrillation patients who couldn’t take warfarin, bleeding rates were similar at about 3.8% per year with aspirin and 4.5% per year with apixaban, a difference that was not statistically significant.⁸ A large comparative study published in JAMA found that patients on apixaban or dabigatran had rates of major bleeding and intracranial hemorrhage similar to those on aspirin.⁹

This does not mean that all anticoagulants are identical in bleeding risk. The same JAMA analysis found that rivaroxaban carried a higher bleeding risk compared with aspirin than the other newer anticoagulants did.⁹ But the overall takeaway is that choosing aspirin over an anticoagulant because you think aspirin is substantially safer is based on an outdated understanding of the risks. You’re accepting much less stroke protection without getting much less bleeding risk in return.

Subclinical Atrial Fibrillation and the Gray Zone

One area where the aspirin question gets genuinely complicated is subclinical atrial fibrillation, where brief episodes of irregular rhythm are picked up by pacemakers, implanted monitors, or wearable devices, but the person has never had symptoms or a standard diagnosis. These patients are at higher risk of stroke than people with no irregular rhythm at all, but their risk is lower than those with sustained, clinically diagnosed atrial fibrillation. So the trade-off between stroke prevention and bleeding is tighter.

The ARTESiA trial addressed exactly this group. Apixaban reduced stroke and systemic embolism compared with aspirin, but it also increased major bleeding.¹⁰ A subgroup analysis from the same trial looked at whether the benefit varied according to a patient’s overall stroke risk score and found that the reduction in stroke with apixaban was consistent, but the absolute benefit was naturally larger in patients at higher baseline risk.¹¹

For someone whose smartwatch flags an occasional episode of atrial fibrillation, the right answer isn’t to start taking aspirin as a hedge. The evidence says aspirin provides only modest protection even in this gray zone, and the conversation with a doctor should focus on whether a proper anticoagulant makes sense based on overall risk factors.

Aspirin Resistance Adds Another Layer of Uncertainty

Even setting aside the fundamental mechanism mismatch between aspirin and atrial fibrillation clots, not everyone responds to aspirin the same way. A phenomenon loosely called aspirin resistance means that in some people, aspirin fails to suppress platelet activity as effectively as expected. Research has found that aspirin resistance may be associated with more severe strokes and larger areas of brain damage when strokes do occur, though this effect is most relevant to strokes caused by arterial disease rather than those caused by atrial fibrillation itself.¹² In other words, for the subset of patients where aspirin could theoretically help, it sometimes doesn’t work well anyway.

Left Atrial Appendage Closure and the Post-Procedure Role of Aspirin

For patients who truly cannot tolerate any anticoagulant, there is a device-based option: left atrial appendage closure, a procedure that plugs the pouch where most atrial fibrillation clots form. After the device is implanted, patients need some type of antithrombotic therapy for a period while tissue grows over the device, and this is one area where aspirin still shows up in treatment plans, typically in combination with another agent.

Recent evidence has shifted even this limited role. A large analysis found that using a direct oral anticoagulant alone after left atrial appendage closure resulted in fewer major adverse events and less major bleeding at 45 days compared with combining a direct oral anticoagulant with aspirin, with no difference in stroke risk or device-related clot formation.¹³ The ANDES randomized trial similarly found that short-term anticoagulant therapy alone after the procedure produced significantly fewer bleeding events than a dual antiplatelet regimen that included aspirin.¹⁴

There is one interesting exception. A study of patients who developed small leaks around their left atrial appendage closure devices found that aspirin alone was associated with significantly fewer bleeding events than combination therapy with direct oral anticoagulants or dual antiplatelet regimens, without any increase in clot-related events.¹⁵ So even in this very narrow post-procedural context, the role of aspirin is evolving and depends on the specific clinical situation.

The Self-Medication Problem

One of the practical dangers around aspirin and atrial fibrillation is that many people reach for aspirin on their own. If you’ve heard that irregular heartbeats raise stroke risk, and you know aspirin is used for heart problems, taking a daily aspirin might seem like common sense. Surveys have found a high prevalence of aspirin self-medication for suspected cardiovascular conditions, and this practice carries its own risks, including gastrointestinal bleeding, without delivering meaningful protection against atrial fibrillation-related stroke.¹⁶

The problem is compounded by the fact that many people with atrial fibrillation don’t know they have it. Episodes can be silent, especially in older adults. Starting aspirin because you occasionally feel your heart flutter gives you a false sense of security. If those flutters are genuinely atrial fibrillation, aspirin is the wrong tool, and if they’re benign palpitations, aspirin is unnecessary and still carries bleeding risks.

When People Already Take Aspirin for Something Else

A separate and genuinely tricky situation arises when someone already takes aspirin for another reason, such as coronary artery disease, and then develops atrial fibrillation. In that case, the doctor adds an anticoagulant for the atrial fibrillation, but the question of whether to continue the aspirin is not straightforward. A chart review of over 200 patients receiving both an anticoagulant and aspirin found that roughly a quarter had originally been placed on aspirin for coronary artery disease and then started on warfarin for atrial fibrillation without anyone discontinuing the aspirin.¹⁷ The combination of aspirin plus an anticoagulant raises bleeding risk, and current thinking leans toward dropping the aspirin once an anticoagulant is on board unless the patient has had a very recent stent or another compelling reason to keep both.

This is a conversation you should have with your doctor rather than managing on your own, because the timing and risk calculation depend on specifics like how recently a stent was placed and how high your stroke risk is.

What Cost and Access Have to Do With It

If anticoagulants are so much better, why would anyone still consider aspirin? In wealthier countries, the answer is increasingly that they wouldn’t. But globally, cost and access still play a role. Warfarin is cheap but requires regular blood monitoring, which is a real barrier in places without accessible lab infrastructure. The newer anticoagulants don’t require monitoring but can be expensive.

An economic analysis based on the ARTESiA trial found that switching from aspirin to apixaban for subclinical atrial fibrillation was actually cost-saving in Canada and the United Kingdom over a few years of treatment, because preventing strokes saves the health system money. In Germany and the United States, though, apixaban cost more because of higher drug prices, with the cost per quality-adjusted life-year gained reaching roughly $85,000 in the U.S.¹⁸ That figure is at the upper edge of what is typically considered cost-effective in American healthcare, and it underscores how drug pricing can influence real-world treatment choices even when the clinical evidence is clear.

In low- and middle-income countries where neither the newer anticoagulants nor reliable warfarin monitoring is available, aspirin may still get used as a default, not because the science supports it, but because the alternatives aren’t accessible. This is a health-systems problem, not a pharmacology problem, and it means that the burden of atrial fibrillation-related stroke falls disproportionately on populations with the least access to effective treatment.